Detailed price information for Jupiter Neurosciences Inc (JUNS-Q) from The Globe and Mail including charting and trades.
New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering"). D. Boral Capital LLC is acti
This is the newest page. Registered accounts read further back.